NASDAQ: AVXL

NASDAQ: AVXL

Alzheimer’s Disease

Advancing groundbreaking therapies to tackle the challenges of neurodegenerative and rare conditions.

What is Alzheimer’s Disease?

Alzheimer’s Disease (AD) is a progressive and irreversible brain disorder that slowly erodes memory, cognitive abilities, and essential functions for independent living. It is the most common form of dementia and poses significant emotional, physical, and financial challenges for individuals and their families.

On a Deeper Level

Alzheimer’s Disease is a neurodegenerative disorder characterized by the abnormal build-up of amyloid plaques and tau tangles in the brain. These changes interfere with the communication between neurons, ultimately leading to cell death. The disease typically begins with mild memory loss and progresses to severe cognitive decline, language difficulties, disorientation, and behavioral changes. Over time, individuals lose their ability to perform everyday tasks, requiring full-time care in advanced stages. While the exact causes of Alzheimer’s are not fully understood, a combination of genetic, environmental, and lifestyle factors is believed to contribute to its onset and progression. Key risk factors include age, family history, and certain health conditions like diabetes and cardiovascular disease.

Signs & Symptoms

The symptoms of Alzheimer’s Disease develop gradually and worsen over time. They include:

  • Memory loss: Forgetting recent events, names, or conversations.
  • Difficulty planning or solving problems: Struggling to follow instructions or manage complex tasks.
  • Confusion with time or place: Losing track of dates, seasons, or current locations.
  • Trouble understanding visual or spatial relationships: Difficulty reading, judging distance, or recognizing faces.
  • Changes in mood and personality: Increased anxiety, depression, irritability, or withdrawal.
  • Challenges with language: Forgetting common words or repeating phrases frequently.

These symptoms significantly impact an individual’s daily life, relationships, and independence.

How many are affected by this condition?

Prevalence

An estimated 7.2 million Americans aged 65 and older are living with Alzheimer’s dementia in 2025, according to the Alzheimer’s Association®. It is the sixth leading cause of death in the United States, and its prevalence is expected to grow as the global population ages. By 2050, the number of Americans living with Alzheimer’s is projected to more than double, posing a substantial public health and economic challenge.

Insights and Data

  • Alzheimer’s Disease is responsible for 60-80% of all dementia cases worldwide (Alzheimer’s Association, 2024).
  • Women are disproportionately affected, accounting for nearly two-thirds of diagnosed cases.
  • The global economic cost of Alzheimer’s and dementia exceeds $1 trillion annually (World Health Organization, 2024).

Our Approach

Anavex’s approach to Alzheimer’s Disease is rooted in innovative science and patient-centered care. By restoring autophagy through SIGMAR1 activation, Blarcamesine (ANAVEX®2-73) promotes neuroprotection and reduces inflammation, addressing the underlying mechanisms of the disease. Our goal is to intervene early, preserving brain function and delaying the progression of symptoms. This targeted therapeutic pathway offers real promise for a future where Alzheimer’s Disease is less overwhelming for patients and their loved ones.

Clinical Progress

Anavex’s groundbreaking candidate, Blarcamesine (ANAVEX®2-73), offers a new approach to treating Alzheimer’s Disease. This small molecule therapy targets the SIGMAR1 receptor to restore cellular balance and protect neurons from stress and degeneration. Phase 2b/3 clinical trials have shown encouraging results, with significant improvements in cognitive and functional measures. Blarcamesine (ANAVEX®2-73) has the potential to slow disease progression and enhance the quality of life for patients.

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

An investigational therapy being studied for Alzheimer’s, Parkinson’s, and Rett syndrome.

Learn more

ANAVEX® 2-73-AD-004

An investigational therapy currently being studied for schizophrenia.

Learn more

ANAVEX® 3-71-001
  • 🟦 = Dark Blue background indicates completed studies
  • 🟧 = Orange background indicates planned and ongoing clinical studies
Learn More About Our Therapeutic Candidates

You are about to leave our website

By clicking “Continue,” you acknowledge that you are leaving the Anavex Life Sciences website and will be redirected to a third-party website operated by NASDAQ or its affiliates.

Anavex Life Sciences does not own, control, maintain, or endorse the content on third-party websites and is not responsible for their accuracy, completeness, or reliability. Any information available through this link is provided by third parties and does not represent the views, opinions, forecasts, or predictions of Anavex Life Sciences or its management.

The linked content is provided for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should rely on their own independent judgment and consult professional advisors before making any investment decisions.

Continue
Go Back